FDA Panel Backs Expanded Peptide Access After Industry-Tied Members Added

An FDA advisory panel voted 8-6 on July 23, 2026, to place BPC-157, TB-500, and KPV on the compounding list — allowing pharmacies to mix these peptides. Over half a dozen members with industry ties joined beforehand, mostly voting yes; academics largely voted no. FDA scientists had flagged insufficient safety data. Health Secretary RFK Jr. calls himself a "big fan."